Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration
Primary Purpose
Insulin Sensitivity
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
erythropoietin
placebo (saline)
Sponsored by
About this trial
This is an interventional basic science trial for Insulin Sensitivity focused on measuring Erythropoietin, human muscle tissue, insulin sensitivity, substrate metabolism
Eligibility Criteria
Inclusion Criteria:
- Healthy persons
- Between 18 and 30 years
- Normal weight (BMI: 18-25)
Exclusion Criteria:
- Severe heart disease (NYHA 3)
- Uncontrolled hypertension
- Previous cerebrovascular disease
- Proliferative retinopathy
- Diabetes
- Musculo-skeletal diseases
Sites / Locations
- Medicinsk forsknings laboratorium
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
placebo
Erythropoietin
Arm Description
placebo
acute administration of erythropoietin
Outcomes
Primary Outcome Measures
Insulin sensitivity
Secondary Outcome Measures
Substrate metabolism
Full Information
NCT ID
NCT00793767
First Posted
November 18, 2008
Last Updated
May 28, 2009
Sponsor
Aarhus University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00793767
Brief Title
Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration
Official Title
Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men
Study Type
Interventional
2. Study Status
Record Verification Date
May 2009
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Aarhus University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Recently EPO receptors have been found in human muscle tissue, but what is still not known is the physiological role of these receptors. In this study the researchers want to investigate if there is any effect of a acute administration of EPO on insulin resistance and/or substrate metabolism in muscle tissue.
Detailed Description
Recently EPO receptors have been found in human muscle tissue, but what is still not known is what the physiological role of these receptors are. It has previously been shown that Growth Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same family of cytokine receptors, and thereby share many of the same signalling pathways. In this study we want to investigate if there is a similar effect on insulin resistance and/or substrate metabolism after acute administration of EPO in human muscle tissue. Different signalling pathways are investigated på western blotting, and insulin sensitivity are measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the forearm model.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Sensitivity
Keywords
Erythropoietin, human muscle tissue, insulin sensitivity, substrate metabolism
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo
Arm Title
Erythropoietin
Arm Type
Experimental
Arm Description
acute administration of erythropoietin
Intervention Type
Drug
Intervention Name(s)
erythropoietin
Intervention Description
bolus of 400 IU/kg
Intervention Type
Drug
Intervention Name(s)
placebo (saline)
Intervention Description
i.v
Primary Outcome Measure Information:
Title
Insulin sensitivity
Time Frame
4 and 6 hours post
Secondary Outcome Measure Information:
Title
Substrate metabolism
Time Frame
4 and 6 hours post
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy persons
Between 18 and 30 years
Normal weight (BMI: 18-25)
Exclusion Criteria:
Severe heart disease (NYHA 3)
Uncontrolled hypertension
Previous cerebrovascular disease
Proliferative retinopathy
Diabetes
Musculo-skeletal diseases
Facility Information:
Facility Name
Medicinsk forsknings laboratorium
City
Århus C
ZIP/Postal Code
8000
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration
We'll reach out to this number within 24 hrs